INVIVYD INC. - COMMON

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

31 May 2024 07:05:00 By Nasdaq GlobeNewswire

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

31 May 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd Elects Two New Independent Members to its Board of Directors

22 May 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

09 May 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

07 May 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

02 May 2024 17:13:02 By Nasdaq GlobeNewswire

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

30 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

15 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Announces CEO Transition

12 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

04 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

22 Mar 2024 15:28:22 By Nasdaq GlobeNewswire

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

22 Mar 2024 15:04:58 By Nasdaq GlobeNewswire

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

05 Feb 2024 16:02:13 By Nasdaq GlobeNewswire

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

09 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

02 Nov 2023 16:01:00 By Nasdaq GlobeNewswire